HIV drug well-tolerated in mid-stage trial, says Avexa

Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will continue to receive 800mg apricitabine twice a day as part of their daily treatment regime. The company expects to release results from the 24 week blinded first phase later this quarter.

To date, 14 patients have completed the full 48 weeks on the trial, and 13 of these have elected to continue on apricitabine treatment in an extension study. The longest treated patient has successfully completed more than 18 months of apricitabine therapy. Although one serious adverse event has been reported, the company said that it was not association with the study drug.

“This data clearly demonstrates that apricitabine is well tolerated in HIV patients. The number of patients requesting to enter the extension study after the 48 week trial to continue treatment with apricitabine is an indicator of the important role that apricitabine will play in the management of HIV. Apricitabine’s clinical development remains on schedule and is demonstrating its potential as a safe and effective treatment for HIV,” said Dr Julian Chick, CEO of Avexa.